TY - JOUR
T1 - Solitary tibial lesion as the initial presentation of Langerhans cell histiocytosis
T2 - report of two cases and literature review
AU - Lin, Chih Yang
AU - Lee, Chia Che
AU - Wu, Kuan Wen
AU - Yuan, Chang Tsu
AU - Kuo, Ken Nan
AU - Wang, Ting Ming
N1 - Publisher Copyright:
© The Author(s) 2021.
PY - 2021
Y1 - 2021
N2 - The various presentations of osseous Langerhans cell histiocytosis (LCH) make it difficult to distinguish from other bone diseases. In addition, there is no universally accepted protocol for managing osseous LCH for single non-central nervous system-risk lesions. Here, the rare cases of two paediatric patients, aged 1 and 2 years, who presented with a solitary tibial lesion at time of LCH diagnosis, are reported. One patient progressed to multiple lesions after curettage of the original lesion. Subsequently, both patients received preventive chemotherapy using the Taiwan Paediatric Oncology Group (TPOG) revised protocol for treating low risk patients with LCH, namely, TPOG LCH2002-LR. After receiving this treatment, which included a schedule of prednisolone and vincristine for 6 weeks, followed by prednisolone, vincristine and 6-mercaptopurine for a further 48 weeks, both patients are free from recurrence or progression.
AB - The various presentations of osseous Langerhans cell histiocytosis (LCH) make it difficult to distinguish from other bone diseases. In addition, there is no universally accepted protocol for managing osseous LCH for single non-central nervous system-risk lesions. Here, the rare cases of two paediatric patients, aged 1 and 2 years, who presented with a solitary tibial lesion at time of LCH diagnosis, are reported. One patient progressed to multiple lesions after curettage of the original lesion. Subsequently, both patients received preventive chemotherapy using the Taiwan Paediatric Oncology Group (TPOG) revised protocol for treating low risk patients with LCH, namely, TPOG LCH2002-LR. After receiving this treatment, which included a schedule of prednisolone and vincristine for 6 weeks, followed by prednisolone, vincristine and 6-mercaptopurine for a further 48 weeks, both patients are free from recurrence or progression.
KW - eosinophilic granuloma
KW - Langerhans cell histiocytosis
KW - LCH
KW - Taiwan Paediatric Oncology Group
UR - http://www.scopus.com/inward/record.url?scp=85099976606&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099976606&partnerID=8YFLogxK
U2 - 10.1177/0300060520982826
DO - 10.1177/0300060520982826
M3 - Article
C2 - 33472472
AN - SCOPUS:85099976606
SN - 0300-0605
VL - 49
JO - Journal of International Medical Research
JF - Journal of International Medical Research
IS - 1
ER -